title: Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection.
abstract: OBJECTIVE
  We hypothesized that the information stemming from biopsy cores can enhance the ability to predict the rate of lymph node invasion (LNI) at radical retropubic prostatectomy (RRP) in men subjected to extended pelvic lymphadenectomy (ePLND).
  
  
  METHODS
  A cohort of 278 consecutive patients (mean age: 66.2 yr) underwent a RRP and an ePLND, in which 10 or more nodes were removed and examined. The median PSA was 7.5 ng/ml. Clinical stage was mostly T1c (59.4%) and T2 (37.8%). Biopsy Gleason sum was 2-5 in 26.6%, 6 in 39.2%, 7 in 27%, and 8-10 in 7.2%. The number of positive cores was 1-19 (median: 4), whilst percentage of positive cores was 7.1-100% (median: 37.5%). Logistic regression models tested the association between the above predictors and LNI. Testing of PSA was coded as either a continuous variable (CV) or a cubic spline (CS). Individual variables and combined accuracy were tested in regression-based nomograms, which were subjected to 10,000 bootstrap resamples to reduce overfit bias.
  
  
  RESULTS
  Mean number of lymph nodes examined was 17.5 (range: 10-38); 29 patients (10.4%) had LNI. Percentage of positive cores (78.5%) and biopsy Gleason sum (78.4%) were the most informative predictors of LNI. A nomogram based on clinical stage, PSA (CV), and biopsy Gleason sum was 79.7% accurate versus 83% (3.3% gain, p<0.001) when percentage of positive cores was added. A 2.7% gain (83.7% vs. 81%; p<0.001) was recorded after the addition of the percentage of positive cores when PSA was coded as a CS.
  
  
  CONCLUSIONS
  Percentage of positive biopsy cores should be considered in prediction of LNI at ePLND, because it significantly improves the combined accuracy of established clinical predictors such as PSA, clinical stage, and biopsy Gleason sum.
authors.affiliation: Department of Urology, Vita-Salute University, Milan, Italy.
authors.forename: Alberto
authors.initials: A
authors.lastname: Briganti
authors.forename: Pierre I
authors.initials: PI
authors.lastname: Karakiewicz
authors.forename: Felix K-H
authors.initials: FK
authors.lastname: Chun
authors.forename: Andrea
authors.initials: A
authors.lastname: Gallina
authors.forename: Andrea
authors.initials: A
authors.lastname: Salonia
authors.forename: Giuseppe
authors.initials: G
authors.lastname: Zanni
authors.forename: Luc
authors.initials: L
authors.lastname: Valiquette
authors.forename: Markus
authors.initials: M
authors.lastname: Graefen
authors.forename: Hartwig
authors.initials: H
authors.lastname: Huland
authors.forename: Patrizio
authors.initials: P
authors.lastname: Rigatti
authors.forename: Francesco
authors.initials: F
authors.lastname: Montorsi
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D001706:Biopsy; D006801:Humans; D016015:Logistic Models; D008197:Lymph Node Excision / Q000379:methods*; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000601:surgery
chemical_list: D017430:Prostate-Specific Antigen